Cingulate Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $71.0M
- Price
- $5.27
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.35%
- Volume
- 163.3K
About
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Quick stats
Shares outstanding13.5M
Computed float8.9M
Float / shares65.8%
Cash runway (months)29.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001862150
Websitehttps://www.cingulate.com
AI Summary
AI-generated1/12
standardmixedearnings
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Cingulate reported second quarter 2026 financial results, ending the period with $28.4 million in cash and cash equivalents, extending its operational runway into mid-2027.
The company is progressing on CMC work to support the resubmission of the NDA for CTx-1301 following a Complete Response Letter, while securing a new U.S. patent covering the asset through December 2042.
Commercialization preparations advanced with the signing of agreements with Prasco for distribution and Indegene for commercial operations, although SG&A expenses doubled to $3.9 million to support this build-out.
Red flags
- SG&A expenses increased 101.5% year-over-year
- Net loss widened to $5.9 million from $5.0 million in the prior year period
- Company operating under the shadow of a Complete Response Letter issued June 1, 2026